

T S1/7

1/7/1

DIALOG(R)File 351:Derwent WPI

(c) 2003 Thomson Derwent. All rts. reserv.

008434544

WPI Acc No: 1990-321544/199043

**Compsn. for external application contg. 2-dimethylamino-ethanol - to improve skin condition, reduce hair loss, etc.**

Patent Assignee: ASCHEMIE MULLER R (ASCH-N); MUELLER AZCHEMIE ROBERT (MUEL-N); MULLER R (MULL-I)

Number of Countries: 014 Number of Patents: 004

Patent Family:

| Patent No   | Kind | Date     | Applicat No | Kind | Date     | Week     |
|-------------|------|----------|-------------|------|----------|----------|
| DE 3912477  | A    | 19901018 | DE 3912477  | A    | 19890415 | 199043 B |
| EP 396857   | A    | 19901114 | EP 90102853 | A    | 19900214 | 199046   |
| JP 2292215  | A    | 19901203 | JP 9096166  | A    | 19900411 | 199103   |
| JP 94018775 | B2   | 19940316 | JP 9096166  | A    | 19900411 | 199414   |

Priority Applications (No Type Date): DE 3912477 A 19890415

Cited Patents: 1.Jnl.Ref; DE 2131946; GB 1182320

Patent Details:

| Patent No | Kind | Lan | Pg | Main IPC | Filing Notes |
|-----------|------|-----|----|----------|--------------|
|-----------|------|-----|----|----------|--------------|

|           |   |  |  |  |  |
|-----------|---|--|--|--|--|
| EP 396857 | A |  |  |  |  |
|-----------|---|--|--|--|--|

Designated States (Regional): AT BE CH DE ES FR GB GR IT LI LU NL SE

|             |    |   |             |                            |
|-------------|----|---|-------------|----------------------------|
| JP 94018775 | B2 | 3 | A61K-031/13 | Based on patent JP 2292215 |
|-------------|----|---|-------------|----------------------------|

Abstract (Basic): DE 3912477 A

Compsn. for external application contains 2-dimethylaminoethanol (I) plus usual formulation materials. (I) is used as a salt or ester, esp. the hydrogencarbonate, citrate, orotate, hydrogentartrate, aceglutamate, acetamidobenzoate or hydrogensuccinate.

USE/ADVANTAGE - The compsns. improve the condition (elasticity and structure) of the skin, preventing premature ageing and development of wrinkles. They also reduce androgen-dependent hair loss and stimulate hair growth. (I) increases protein synthesis and prolongs the livetime of (post)mitotic fibroblasts. (I) is already known for internal use as a psychopharmaceutical and for treatment of geriatric disorders. (3pp Dwg.No.0/0)

Derwent Class: B05; D21; E16

International Patent Class (Main): A61K-031/13

International Patent Class (Additional): A61K-007/06; A61K-007/48

?